Results 281 to 290 of about 9,201,564 (391)

Targeting H3K4 trimethylation in Huntington disease

Proceedings of the National Academy of Sciences of the United States of America, 2013
Malini Vashishtha, C. Ng, F. Yildirim, T. A. Gipson, I. H. Kratter, L. Bodai, Wan-Doo Song, Alice L. Lau, Adam T. Labadorf, Annie Vogel-Ciernia, Juan C. Troncosco, C. Ross, G. Bates, D. Krainc, Ghazaleh Sadri‐Vakili, S. Finkbeiner, J. Marsh, D. Housman, E. Fraenkel, L. Thompson   +19 more
semanticscholar   +1 more source

Deciphering Sequence Determinants of Zygotic Genome Activation Genes: Insights From Machine Learning and the ZGAExplorer Platform

Cell Proliferation, EarlyView.
We compiled a comprehensive set of ZGA genes from mice, humans, pigs, bovines and goats, demonstrating the cross‐species conservation. An interpretable machine learning model, based on k‐mer core features, accurately predicted ZGA genes, revealing abundant and intricate six‐base sequence‐specific patterns and potential binding TFs.
Jixiang Xing, Siqi Yang, Yuchao Liang, Pengwei Hu, Bingjie Dai, Hanshuang Li, Yongqiang Xing, Yongchun Zuo   +7 more
wiley   +1 more source

Atypical Presentations of Huntington Disease-like 2 in South African Individuals. [PDF]

Mov Disord Clin Pract
Narotam-Jeena H, Guttman M, van Hillegondsberg L, van Coller R, Krause A, Carr J.   +5 more
europepmc   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

Cell Proliferation, EarlyView.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang, Yue‐Yue Wang, Ri Wen, Tie‐Ning Zhang, Ni Yang   +4 more
wiley   +1 more source

Integrative determination of atomic structure of mutant huntingtin exon 1 fibrils implicated in Huntington disease. [PDF]

Nat Commun
Bagherpoor Helabad M, Matlahov I, Kumar R, Daldrop JO, Jain G, Weingarth M, van der Wel PCA, Miettinen MS.   +7 more
europepmc   +1 more source

Poster 6: Triglyceride-Lowering Effects of EPA in Individuals with Huntington Disease

, 2008
Robert Block, E. Ray Dorsey, Christopher A. Beck, Ira Shoulson   +3 more
openalex   +1 more source

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

Cell Proliferation, EarlyView.
CRISPR‐Cas systems offer transformative genome editing capabilities for precise manipulation of cellular genes. This enables two main therapeutic avenues: ex vivo modification of patient cells for re‐transplantation or direct in vivo gene targeting via advanced delivery methods.
Bahareh Farasati Far, Marziyeh Akbari, Mohammad Amin Habibi, Morteza Katavand, Sherko Nasseri   +4 more
wiley   +1 more source

Digital assessment of speech in Huntington disease. [PDF]

Front Neurol
Nunes AS, Pawlik M, Mishra RK, Waddell E, Coffey M, Tarolli CG, Schneider RB, Dorsey ER, Vaziri A, Adams JL.   +9 more
europepmc   +1 more source

Symptomatic Treatment of Huntington Disease

, 2008
Octavian Adam, Joseph Jankovic
openalex   +1 more source

A closer look at Doleac and Mukherjee (2022) and the effects of naloxone access laws on opioid ER admissions

Economic Inquiry, EarlyView.
Abstract In their 2022 study, ‘The Effects of Naloxone Access Laws on Opioid Abuse, Mortality, and Crime,’ Doleac and Mukherjee conclude that broadening access to a life‐saving drug—naloxone—does not reduce opioid‐related mortality as the drug simultaneously encourages riskier drug use. I show issues with their data, design, and estimation methods. For
Sergey Alexeev
wiley   +1 more source